Benzinga | Nov 4, 2021 09:17AM EDT

Volition Veterinary Presents 2 Posters At 2021 Veterinary Cancer Society Conference

VolitionRx Limited (NYSE:VNRX) ("Volition"), a multi-national epigenetics company developing simple, easy to use, cost effective blood tests to help diagnose and monitor a range of cancers and other life-altering diseases in both humans and animals, is presenting two abstracts at the 2021 Veterinary Cancer Society (VCS) Virtual Annual Conference, which takes place from Thursday, November 4 through Saturday, November 6.



Dr. Tom Butera, Chief Executive Officer of Volition Veterinary Diagnostics Development, LLC said "Being able to use the Nu.Q(r) Test to not only screen for cancer and help identify disease earlier, but also to monitor the disease progression as an early indication that a dog is coming out of remission, will meet a real unmet need in the market. We expect this disease monitoring product will be our second Nu.Q(r) Vet product . We believe that this product has significant potential to help improve the treatment and the quality of life for dogs as well as providing valuable additional information to inform the clinical decision-making process for the veterinarian and pet owner. Whilst the veterinary commercial team has been busy negotiating global licensing and distribution arrangements, I'd like to commend the hard work and joint research efforts of the Texas A&M University and Volition team; we are delighted to present these two studies at the world's leading veterinary oncology conference."

"The data demonstrate that Nu.Q(r) Vet may serve as a more sensitive measurement of both minimal residual disease and remission and could be a useful monitoring test for dogs with cancer. Given Nu.Q(r) is a simple blood test it would be incredibly useful in the clinic and general practitioner veterinarian's office," said Dr. Heather Wilson-Robles, Professor at Texas A&M University, Chief Medical Officer of Volition Veterinary Diagnostics Development LLC, and President of the VCS.

Dr. Robles added, "The second poster reports our first study using Nu.Q(r) Capture, Volition's enrichment tool, to better understand the types of circulating nucleosomes and their genome patterns in the plasma of dogs with lymphoma. It was exciting to see that once again the animal data shows similar findings to human studies in that canine lymphoma patients have circulating nucleosomes lacking linker DNA (i.e., shorter nucleosomes) that are not detected in plasma from healthy canines and that Nu.Q(r) Capture is capable of enriching canine cancer-associated nucleosomes in plasma of lymphoma patients. We look forward to expanding our research in this area."

https://youtu.be/-rifOI0LrgA